Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Objectives: Spain was among the first countries to implement universal prophylaxis for respiratory syncytial virus (RSV) using nirsevimab, leading to a 60%-80% reduction in bronchiolitis hospital admissions. The main objective of this study was to describe the characteristics of infants admitted with bronchiolitis after RSV prophylaxis had been established.
Methods: A retrospective study was conducted in 15 Spanish pediatric emergency departments during the 2023-2024 RSV season. We reviewed medical records coded as "acute bronchiolitis" of infants aged less than 12 months who were hospitalized.
Results: A total of 947 infants with bronchiolitis were included. Of these, 198 (20.9%) were ineligible for immunization because they were older than 6 months and had no comorbidities. Among the 749 (79.1%) infants who met the criteria for immunization, 377 (50.3%) received nirsevimab, of whom 159 (42.1%) tested positive for RSV, while 372 (49.7%) were not immunized, with 322 (86.5%) testing positive for RSV (p < 0.001). Among infants who were not immunized, the most common reason for not receiving nirsevimab was family refusal. Among infants with RSV bronchiolitis, there were no significant differences in PICU admission rates or length of stay between those who were immunized and those who were not.
Conclusion: During the first nirsevimab campaign, most bronchiolitis admissions involved healthy children over 6 months of age who were not included in the target population, eligible infants who were not immunized, and immunized infants with non-RSV bronchiolitis. Further studies are needed to analyze the characteristics of immunized patients who are admitted with RSV bronchiolitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ppul.71249 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe viral infections requiring intensive care unit admissions- aetiology, co-infections, respiratory interventions and outcomes.
Infection
September 2025
General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, UK.
Introduction: Severe viral infections are common in patients requiring admission to intensive care units (ICU). Furthermore, these patients often have additional secondary or co-infections. Despite their prevalence, it remains uncertain to what extent those additional infections contribute to worse outcomes for patients with severe viral infections requiring ICU admission.
View Article and Find Full Text PDFLongitudinal Extensive Transverse Myelitis After Respiratory Syncytial Virus Vaccination With Positive Anti-Recoverin Antibodies.
Case Rep Neurol Med
August 2025
First Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Stilponos Kyriakidi 1, Thessaloniki, Greece.
Longitudinal extensive transverse myelitis (LETM) is a rare adverse event after vaccination. We present a case of severe myelitis in a 76-year-old man with positive anti-recoverin antibodies that occurred one week after RSVPreF3 vaccination against respiratory syncytial virus (RSV). The patient presented with severe spastic paraparesis, urinary retention, postural tremor of the upper extremities, hypesthesia, severely impaired proprioception and vibration sense in the lower extremities, and tonic spasms of the lower extremities.
View Article and Find Full Text PDFChanging in epidemiology of respiratory syncytial virus infection among children younger than 5 years old during COVID-19 pandemic in northern Taiwan.
J Microbiol Immunol Infect
September 2025
Department of Pediatrics, MacKay Children's Hospital and MacKay Memorial Hospital, Taipei, Taiwan.
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants and young children. The COVID-19 pandemic significantly disrupted global RSV epidemiology. This study aimed to investigate the impact of the pandemic on RSV epidemiology in northern Taiwan from 2018 to 2023.
View Article and Find Full Text PDFRespiratory Syncytial Virus Epidemiology and Clinical Burden in High-Risk and ≥ 50-Year-Old Adults in Low- to Middle-Income Countries: An Artificial-Intelligence-Enabled Systematic Literature Review.
Infect Dis Ther
September 2025
GSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium.
Introduction: Limited data are available on the epidemiology and clinical burden of respiratory syncytial virus (RSV) among adults with underlying medical or immunocompromising conditions ("high-risk adults") and ≥ 50-year-old adults in developing countries.
Methods: To better understand the impact of RSV in these populations, a systematic literature review of articles published from the year 2000 onward reporting RSV data among high-risk 18-59-year-old adults and ≥ 50-year-old adults in low, lower-middle, upper-middle, and selected high-income countries was undertaken. Searches were run on Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica DataBASE (EMBASE), and were supplemented by additional searches (e.
Evaluation of a real-time hospital surveillance system for respiratory syncytial virus, Ontario, Canada, 2022-2023.
Can Commun Dis Rep
August 2025
Ministry of Health, Toronto, ON.
Background: Respiratory syncytial virus (RSV) surged in the 2022-2023 respiratory season after low activity during the pandemic. To monitor the RSV season in real time and support healthcare planning, Ontario introduced daily hospital bed census reporting of RSV hospitalizations by age group (0-17, 18-64, 65 years and older).
Objectives: To assess the completeness and quality of the newly introduced real-time surveillance compared to end-of-season ICD-10 coded hospitalization discharge abstract data (DAD) from November 22, 2022, to March 31, 2023.